A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects

• Главные авторы: Xu Jiang (Автор), Kyung-Sang Yu (Автор), Dong Hyuk Nam (Автор), Jaeseong Oh (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2024-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is commonly used for the treatment of type 2 diabetes mellitus (T2DM). CKD-370 was newly developed as a cocrystal formulation of empagliflozin with co-former L-proline, which has been confirmed to be bioequivalent in South Kore...